{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:54:38Z","timestamp":1770746078336,"version":"3.49.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":246,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Grant of the Korea Health Technology R&D Project"},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health & Welfare, Republic of Korea","award":["RS-2023-00262321"],"award-info":[{"award-number":["RS-2023-00262321"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) is the most lethal and incurable brain tumor, with limited treatment options. Systemic delivery of many promising drugs has proven inefficacious due to insufficient brain penetrance. Convection-enhanced delivery (CED) enables direct intracranial infusion of high drug concentrations. However, CED is impaired by rapid drug clearance from the brain, which diminishes its therapeutic benefits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To develop CED-injectable therapeutics for GBM treatment, two polypeptides, XM147 and XM161, were engineered through tandem recombination of IL4R\u03b1- or IL13R\u03b12-specific ligands with thermally responsive motifs. XM147-AZDye647 was created by labeling XM147 with the fluorescent dye AZDye647 to study clearance kinetics. Polypeptide-drug conjugates (PDCs), XM147-SN38 and XM161-SN38, were generated by conjugating these polypeptides with the topoisomerase I inhibitor SN38, which is potent but too toxic for use without a drug carrier. The antitumor efficacy of CED-infused XM147-SN38 and XM161-SN38 was evaluated in intracerebral GBM mouse models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>XM147 and XM161 exhibited high selectivity and strong binding avidity for their respective receptors. Pharmacokinetic studies of XM147-AZDye647 in non-tumor-bearing mice demonstrated markedly prolonged brain retention following CED. In GBM xenografts, CED-administered XM147-SN38 and XM161-SN38 effectively suppressed tumor growth and significantly extended median survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These findings provide evidence supporting the use of CED-infused, long-acting PDCs a promising therapeutic strategy for GBM treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf187","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T11:41:20Z","timestamp":1756467680000},"source":"Crossref","is-referenced-by-count":0,"title":["Self-assembling polypeptide-drug conjugates as innovative therapeutic candidates for glioblastoma treatment by enhancing intracranial residence time"],"prefix":"10.1093","volume":"7","author":[{"given":"Yunjeong","family":"Gwon","sequence":"first","affiliation":[{"name":"Excellamol Inc. , R&D Center, Daegu ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Eun","family":"Kim","sequence":"additional","affiliation":[{"name":"Excellamol Inc. , R&D Center, Daegu ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wooram","family":"Jung","sequence":"additional","affiliation":[{"name":"DT&CRO, Efficacy Evaluation Center , Gyeonggi-do ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soobin","family":"Kim","sequence":"additional","affiliation":[{"name":"DT&CRO, Efficacy Evaluation Center , Gyeonggi-do ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyuri","family":"Shin","sequence":"additional","affiliation":[{"name":"DT&CRO, Efficacy Evaluation Center , Gyeonggi-do ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yejin","family":"Lee","sequence":"additional","affiliation":[{"name":"CLEVERcns, Seoul National University Hospital , Seoul ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoori","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University , Seoul ,","place":["Republic of Korea"]},{"name":"Department of Nuclear Medicine, Seoul National University Hospital , Seoul ,","place":["Republic of Korea"]},{"name":"CLEVERcns, Seoul National University Hospital , Seoul ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi Jeong","family":"Cheon","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University , Seoul ,","place":["Republic of Korea"]},{"name":"Department of Nuclear Medicine, Seoul National University Hospital , Seoul ,","place":["Republic of Korea"]},{"name":"CLEVERcns, Seoul National University Hospital , Seoul ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-1045","authenticated-orcid":false,"given":"Won Bae","family":"Jeon","sequence":"additional","affiliation":[{"name":"DGIST, Division of Biomedical Technology , Daegu ,","place":["Republic of Korea"]},{"name":"Excellamol Inc. , R&D Center, Daegu ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"2025091922073319600_CIT0001","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","article-title":"CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010\u20132014.","volume-title":"Neuro Oncol.","author":"Ostrom","year":"2017"},{"issue":"6","key":"2025091922073319600_CIT0002","doi-asserted-by":"crossref","first-page":"422","DOI":"10.32074\/1591-951X-830","article-title":"Paediatric type diffuse high-grade gliomas in the 5th CNS WHO Classification","volume":"114","author":"Gianno","year":"2022","journal-title":"Pathologica."},{"issue":"10","key":"2025091922073319600_CIT0003","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"22","key":"2025091922073319600_CIT0004","doi-asserted-by":"crossref","first-page":"12324","DOI":"10.1073\/pnas.1921531117","article-title":"Fisher Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma","volume":"117","author":"Rajesh","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2025091922073319600_CIT0005","first-page":"vdad033","article-title":"Overcoming translational barriers in H3K27-altered diffuse midline glioma: Increasing the drug-tumor residence time","volume":"5","author":"Power","year":"2023","journal-title":"Neurooncol. Adv."},{"issue":"11","key":"2025091922073319600_CIT0006","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1158\/0008-5472.CAN-10-0906","article-title":"Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors","volume":"71","author":"Lopez","year":"2011","journal-title":"Cancer Res."},{"issue":"3","key":"2025091922073319600_CIT0007","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3171\/2018.2.PEDS17663","article-title":"The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery","volume":"22","author":"Singleton","year":"2018","journal-title":"J Neurosurg Pediatr"},{"issue":"6","key":"2025091922073319600_CIT0008","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/neuonc\/noac285","article-title":"Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial","volume":"25","author":"Sampson","year":"2023","journal-title":"Neuro Oncol"},{"issue":"8","key":"2025091922073319600_CIT0009","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/neuonc\/nop054","article-title":"Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma","volume":"12","author":"Kunwar","year":"2010","journal-title":"Neuro Oncol"},{"issue":"5","key":"2025091922073319600_CIT0010","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3390\/pharmaceutics14050922","article-title":"IL-13R\u03b12 status predicts GB-13 (IL13.E13K-PE4E) efficacy in high-grade glioma","volume":"14","author":"Rechberger","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9","key":"2025091922073319600_CIT0011","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2967\/jnumed.123.266365","article-title":"Theranostic intratumoral convection-enhanced delivery of 124I-omburtamab in patients with diffuse intrinsic pontine glioma: Pharmacokinetics and lesion dosimetry","volume":"65","author":"Pandit-Taskar","year":"2024","journal-title":"J Nucl Med."},{"issue":"1","key":"2025091922073319600_CIT0012","first-page":"vdac130","article-title":"Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Sepatux-M in glioblastoma patient-derived xenografts","volume":"4","author":"Kendra","year":"2022","journal-title":"Neurooncol. Adv.."},{"issue":"3","key":"2025091922073319600_CIT0013","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1215\/15228517-2006-001","article-title":"Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model","volume":"8","author":"Saito","year":"2006","journal-title":"Neuro Oncol"},{"issue":"8","key":"2025091922073319600_CIT0014","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1021\/acsabm.2c00215","article-title":"Intrinsically disordered protein micelles as vehicles for convection-enhanced drug delivery to glioblastoma multiforme","volume":"5","author":"Gleason","year":"2022","journal-title":"ACS Appl Bio Mater"},{"issue":"10","key":"2025091922073319600_CIT0015","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/neuonc\/noaa101","article-title":"A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment","volume":"22","author":"Bellat","year":"2020","journal-title":"Neuro Oncol"},{"issue":"2","key":"2025091922073319600_CIT0016","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/neuonc\/noac173","article-title":"Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro Oncol"},{"issue":"6","key":"2025091922073319600_CIT0017","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","article-title":"Convection-enhanced delivery of macromolecules in the brain","volume":"91","author":"Bobo","year":"1994","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"2025091922073319600_CIT0018","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3171\/2012.10.PEDS12142","article-title":"Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children","volume":"11","author":"Anderson","year":"2013","journal-title":"J Neurosurg Pediatr"},{"issue":"11","key":"2025091922073319600_CIT0019","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(22)00599-X","article-title":"Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial","volume":"23","author":"Spinazzi","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"2025091922073319600_CIT0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cyto.2015.05.023","article-title":"Commentary: IL-4 and IL-13 receptors and signaling","volume":"75","author":"McCormick","year":"2015","journal-title":"Cytokine."},{"issue":"4","key":"2025091922073319600_CIT0021","doi-asserted-by":"crossref","first-page":"e0193565","DOI":"10.1371\/journal.pone.0193565","article-title":"IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma","volume":"13","author":"Berlow","year":"2018","journal-title":"PLoS One."},{"issue":"10","key":"2025091922073319600_CIT0022","doi-asserted-by":"crossref","first-page":"e77769","DOI":"10.1371\/journal.pone.0077769","article-title":"Glioma IL13R\u03b12 is associated with mesenchymal signature gene expression and poor patient prognosis","volume":"8","author":"Brown","year":"2013","journal-title":"PLoS One."},{"issue":"2","key":"2025091922073319600_CIT0023","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/jbm.a.33041","article-title":"Stimulation of fibroblasts and neuroblasts on a biomimetic extracellular matrix consisting of tandem repeats of the elastic VGVPG domain and RGD motif","volume":"97","author":"Jeon","year":"2011","journal-title":"J Biomed Mater Res A."},{"key":"2025091922073319600_CIT0024","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jconrel.2022.01.024","article-title":"Intratumoral delivery of brachytherapy and immunotherapy by a thermally triggered polypeptide depot","volume":"343","author":"Kelly","year":"2022","journal-title":"J Control Release."},{"issue":"Suppl 8","key":"2025091922073319600_CIT0025","doi-asserted-by":"crossref","first-page":"viii121","DOI":"10.1093\/neuonc\/noae165.0469","article-title":"DDEL-02. Preclinical efficacy of IL13R\u03b12 -targeting polypeptide-drug conjugate (Self-DepotTM OncoPDC) in glioblastoma and diffuse intrinsic pontine glioma","volume":"26","author":"Jeon","year":"2024","journal-title":"Neuro Oncol"},{"issue":"16","key":"2025091922073319600_CIT0026","doi-asserted-by":"crossref","first-page":"15291","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med."},{"issue":"12","key":"2025091922073319600_CIT0027","doi-asserted-by":"crossref","first-page":"e81891","DOI":"10.1371\/journal.pone.0081891","article-title":"Construction and application of elastin like polypeptide containing IL-4 receptor targeting peptide","volume":"8","author":"Sarangthem","year":"2013","journal-title":"PLoS One."},{"issue":"48","key":"2025091922073319600_CIT0028","doi-asserted-by":"crossref","first-page":"46073","DOI":"10.1074\/jbc.M209560200","article-title":"Kinetic analysis of the interleukin-13 receptor complex","volume":"277","author":"Andrews","year":"2002","journal-title":"J Biol Chem."},{"issue":"10","key":"2025091922073319600_CIT0029","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1021\/acs.biomac.4c00640","article-title":"Affibody-functionalized elastin-like peptide-drug conjugate nanomicelle for targeted ovarian cancer therapy","volume":"25","author":"Li","year":"2024","journal-title":"Biomacromolecules"},{"issue":"63","key":"2025091922073319600_CIT0030","doi-asserted-by":"crossref","first-page":"16783","DOI":"10.1002\/chem.201803725","article-title":"Bioorthogonal uncaging of the active metabolite of irinotecan by palladium-functionalized microdevices","volume":"24","author":"Adam","year":"2018","journal-title":"Chemistry"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf187\/64208412\/vdaf187.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf187\/64208412\/vdaf187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf187\/64208412\/vdaf187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T02:07:43Z","timestamp":1758334063000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf187\/8247902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf187","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf187"}}